NeoGenomics (NASDAQ:NEO) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a $19.00 target price on the medical research company’s stock.

NEO has been the topic of a number of other research reports. Benchmark reaffirmed a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a research note on Tuesday, September 24th. Stephens reaffirmed an “overweight” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.89.

NeoGenomics Trading Up 3.5 %

NASDAQ NEO opened at $15.46 on Wednesday. The company has a market cap of $1.98 billion, a P/E ratio of -24.94 and a beta of 1.19. NeoGenomics has a 12 month low of $12.77 and a 12 month high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The company has a 50-day moving average of $14.71 and a 200-day moving average of $14.73.

Institutional Investors Weigh In On NeoGenomics

Institutional investors have recently added to or reduced their stakes in the stock. Natixis Advisors LLC lifted its position in shares of NeoGenomics by 54.1% in the third quarter. Natixis Advisors LLC now owns 33,982 shares of the medical research company’s stock worth $501,000 after purchasing an additional 11,936 shares in the last quarter. Royce & Associates LP boosted its position in NeoGenomics by 3.2% during the third quarter. Royce & Associates LP now owns 639,476 shares of the medical research company’s stock valued at $9,432,000 after purchasing an additional 19,780 shares during the last quarter. KBC Group NV grew its stake in NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,127 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of NeoGenomics during the 3rd quarter worth approximately $1,101,000. Finally, Fernwood Investment Management LLC raised its stake in shares of NeoGenomics by 1.0% during the 3rd quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after purchasing an additional 900 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.